Validation of Minnesota acute graft- versus -host disease Risk Score
Open Access
- 18 July 2019
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 105 (2) , 519-524
Abstract
Using multicenter data, we developed a novel acute graft-versus-host disease Risk Score which more accurately predicts response to steroid treatment, survival and transplant related mortality than other published risk scores based upon clinical grading criteria.1 To validate this Risk Score in a contemporary cohort, we examined 355 recent University of Minnesota patients (2007-2016) diagnosed with acute graft-versus-host disease and treated with prednisone 60 mg/m2/day for 14 days, followed by an 8-week taper. Overall response [complete response + partial response] was higher in the 276 standard risk versus 79 high risk graft-versus-host disease patients at day 14 (71% versus 56%, PP=0.02) and day 56 (68% versus 49%, Pversus-host disease grade. In multiple regression analysis, patients with high risk graft-versus-host disease were less likely to respond at day 28 (odds ratio 0.5, 95% CI 0.3-0.9, PP=0.03) and overall mortality (Hazard Ratio 1.7, 95% CI, 1.2-2.4, Pversus-host disease. This analysis confirms the Minnesota graft-versus-host disease Risk Score as a valuable bedside tool to define risk in patients with acute graft-versus-host disease. A tailored approach to upfront acute graft-versus-host disease therapy based upon the Minnesota Risk Score may improve outcomes and facilitate testing of novel treatments in these patients.Keywords
This publication has 16 references indexed in Scilit:
- Acute Graft-versus-Host Disease — Biologic Process, Prevention, and TherapyNew England Journal of Medicine, 2017
- Allele-Level HLA Matching Impacts Key Outcomes Following Umbilical Cord Blood Transplantation for Inherited Metabolic DisordersTransplantation and Cellular Therapy, 2017
- Alternative donor hematopoietic cell transplantation for Fanconi anemiaBlood, 2015
- What predicts high risk acute graft‐versus‐host disease (GVHD) at onset?: identification of those at highest risk by a novel acuteGVHDrisk scoreBritish Journal of Haematology, 2012
- Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort reportBlood, 2011
- 1994 Consensus Conference on Acute GVHD Grading.1995
- TREATMENT OF MODERATE AND SEVERE ACUTE GVHD AFTER ALLOGENEIC BONE MARROW TRANSPLANTATIONTransplantation, 1994
- PREDNISONE THERAPY FOR ACUTE GRAFT-VERSUS-HOST DISEASETransplantation, 1993
- Bone-Marrow TransplantationNew England Journal of Medicine, 1975
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974